New injection could boost heart function in lung disease patients
NCT ID NCT07177703
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 32 times
Summary
This study tests whether adding an injectable medication called treprostinil to standard oral therapy can improve heart function in people with intermediate-risk pulmonary arterial hypertension (PAH). About 32 adults will receive the drug and be monitored for 3 months, with follow-up lasting up to 2 years. The main goal is to see if the right side of the heart pumps more blood with each beat, measured by a special heart MRI.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.